GlassScriptPhysician profile
James M Hunt
NPI 1437205069
$9,158.12
in general payments reported to CMS, 2019-2025
24 companies · $608 in 2025
The $608 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.26 · 2020: $283 · 2021: $209 · 2022: $871 · 2023: $5,736 · 2024: $1,403 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Food and Beverage: $2,681 · Travel and Lodging: $1,867 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Food and Beverage | $2,680.73 |
| Travel and Lodging | $1,866.73 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,162.76 | 2023-2024 | Ion, Da Vinci Surgical System |
| Inari Medical, INC. | $877.67 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Actelion Pharmaceuticals US, INC. | $581.16 | 2024-2025 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $315.80 | 2022-2025 | Breztri, Fasenra, Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $273.17 | 2023-2025 | |
| Glaxosmithkline, LLC. | $184.61 | 2021-2025 | Trelegy Ellipta |
| Abiomed | $175.91 | 2019-2024 | Impella |
| Veran Medical Technologies, INC. | $164.53 | 2020 | |
| Abbott Laboratories | $142.94 | 2023 | Xact |
| Siemens Medical Solutions USA, INC. | $138.49 | 2024 | |
| Merck Sharp & Dohme LLC | $134.82 | 2024-2025 | Winrevair, Zerbaxa, Recarbrio |
| Genzyme Corporation | $131.64 | 2022-2025 | |
| Edwards Lifesciences Corporation | $129.92 | 2023 | |
| Inspire Medical Systems, INC. | $118.79 | 2020 | |
| Pulmonx Corporation | $109.25 | 2023 | Zephyr Delivery Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $108.50 | 2022-2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $84.22 | 2021-2025 | Tyvaso |
| Insmed, INC. | $82.97 | 2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $82.45 | 2023-2025 | Dupixent |
| Harmony Biosciences LLC | $45.79 | 2024 | |
| Scpharmaceuticals INC. | $38.97 | 2024-2025 | |
| Mylan Specialty L.P. | $36.02 | 2021 | |
| Liquidia Technologies, INC. | $23.45 | 2025 | Yutrepia |
| Genentech USA, INC. | $14.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.